Loading…
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $134M | $-36M | $-39M | $-19M | -14.1% | -3.9% | - |
| 2024 | $140M | $-24M | $-27M | $-22M | -9.8% | 57.1% | - |
| 2023 | $89M | $-41M | $-49M | $-46M | -30.3% | 81.8% | - |
| 2022 | $49M | $-58M | $-67M | $-61M | -74.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 49.01 | 89.08 | 139.93 | 134.48 |
| Cost Of Revenue | 27.68 | 35.31 | 40.98 | 31.47 |
| Gross Profit | 21.33 | 53.77 | 98.94 | 103.01 |
| Operating Expense | 84.65 | 103.85 | 135.80 | 151.20 |
| Operating Income | -63.32 | -50.09 | -36.86 | -48.19 |
| EBITDA | -57.78 | -41.20 | -23.81 | -35.59 |
| EBIT | -61.80 | -45.28 | -27.38 | -38.86 |
| Pretax Income | -66.75 | -48.59 | -27.41 | -38.88 |
| Tax Provision | 0.01 | 0.02 | 0.05 | 0.07 |
| Net Income | -66.76 | -48.61 | -27.45 | -38.94 |
| Net Income Common Stockholders | -66.76 | -48.61 | -27.45 | -38.94 |
| Total Expenses | 112.32 | 139.16 | 176.78 | 182.67 |
| Interest Expense | 4.95 | 3.31 | 0.02 | 0.02 |
| Interest Income | 1.52 | 6.57 | 9.47 | 9.33 |
| Research And Development | 25.98 | 29.05 | 34.37 | 38.55 |
| Selling General And Administration | 58.66 | 74.80 | 101.43 | 112.65 |
| Normalized EBITDA | -57.78 | -39.43 | -23.81 | -35.59 |
| Normalized Income | -66.76 | -46.84 | -27.45 | -38.94 |
| Basic EPS | -2.41 | -1.41 | -0.71 | 0 |
| Diluted EPS | -2.41 | -1.41 | -0.71 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Total Unusual Items | 0 | -1.77 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | -1.77 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -66.76 | -48.61 | -27.45 | -38.94 |
| Reconciled Depreciation | 4.02 | 4.08 | 3.58 | 3.27 |
| Reconciled Cost Of Revenue | 27.68 | 35.31 | 40.98 | 31.47 |
| Net Interest Income | -3.43 | 3.27 | 9.45 | 9.31 |
| Net Income From Continuing And Discontinued Operation | -66.76 | -48.61 | -27.45 | -38.94 |
| Total Operating Income As Reported | -63.32 | -50.09 | -36.86 | -48.19 |
| Diluted Average Shares | 27.66 | 34.46 | 38.87 | 0 |
| Basic Average Shares | 27.66 | 34.46 | 38.87 | 0 |
| Diluted NI Availto Com Stockholders | -66.76 | -48.61 | -27.45 | -38.94 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -66.76 | -48.61 | -27.45 | -38.94 |
| Net Income Continuous Operations | -66.76 | -48.61 | -27.45 | -38.94 |
| Other Income Expense | 0 | -1.77 | 0 | 0 |
| Special Income Charges | 0 | -1.77 | 0 | 0 |
| Gain On Sale Of Ppe | 0 | 0 | 0 | 0 |
| Other Special Charges | 0 | 1.77 | 0 | 0 |
| Gain On Sale Of Security | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -3.43 | 3.27 | 9.45 | 9.31 |
| Interest Expense Non Operating | 4.95 | 3.31 | 0.02 | 0.02 |
| Interest Income Non Operating | 1.52 | 6.57 | 9.47 | 9.33 |
| Operating Revenue | 49.01 | 89.08 | 139.93 | 134.48 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| RxSight, Inc.this co. | RXST | $282M | - | 1.02 | -14.1% | -1.42 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Simulations Plus, Inc. | SLP | $283M | - |
| 2.11 |
| -51.9% |
| 17.29 |
| Foghorn Therapeutics Inc. | FHTX | $279M | - | -2.49 | 68.5% | -2.05 |
| Editas Medicine, Inc. | EDIT | $276M | - | 10.11 | -586.6% | -1.57 |
| Accendra Health, Inc. | ACH | $267M | - | -0.58 | 238.8% | 5.96 |
| Eledon Pharmaceuticals, Inc. | ELDN | $266M | - | 1.84 | -56.3% | - |
| Peer Median | - | 15.33 | 1.20 | -29.1% | 0.09 | |